EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Immix Biopharma's enterprise value is $25.40 Mil.
Immix Biopharma's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil. Therefore, Immix Biopharma's EV-to-Revenue for today is .
The historical rank and industry rank for Immix Biopharma's EV-to-Revenue or its related term are showing as below:
IMMX's EV-to-Revenue is not ranked *
in the Biotechnology industry.
Industry Median: 7.86 * Ranked among companies with meaningful EV-to-Revenue only.
As of today (2024-06-10), Immix Biopharma's stock price is $2.03.
Immix Biopharma's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00. Therefore, Immix Biopharma's PS Ratio for today is .
Immix Biopharma EV-to-Revenue Historical Data
The historical data trend for Immix Biopharma's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Immix Biopharma's EV-to-Revenue
For the Biotechnology subindustry, Immix Biopharma's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Immix Biopharma's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Immix Biopharma's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Immix Biopharma's EV-to-Revenue falls into.
Immix Biopharma's current Enterprise Value is $25.40 Mil.
Immix Biopharma's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Immix Biopharma's share price for today is $2.03.
Immix Biopharma's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Immix Biopharma EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Immix Biopharma's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Immix Biopharma (Immix Biopharma) Business Description
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. It has two business units ImmixBio and Nexcella.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
IMMX has been successfully added to your 